Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Alaunos Therapeutics (TCRT) EBIT Margin (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed EBIT Margin for 13 consecutive years, with 54600.0% as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, EBIT Margin rose 11960000.0% year-over-year to 54600.0%, compared with a TTM value of 67883.33% through Sep 2025, up 13223333.0%, and an annual FY2024 reading of 48120.0%, up 63722000.0% over the prior year.
  • EBIT Margin was 54600.0% for Q1 2025 at Alaunos Therapeutics, down from 18875.0% in the prior quarter.
  • Across five years, EBIT Margin topped out at 77463.64% in Q4 2022 and bottomed at 794900.0% in Q4 2023.
  • Average EBIT Margin over 5 years is 175224.73%, with a median of 41875.0% recorded in 2024.
  • The sharpest move saw EBIT Margin crashed -87236364bps in 2023, then skyrocketed 77602500bps in 2024.
  • Year by year, EBIT Margin stood at 552550.0% in 2021, then surged by 114bps to 77463.64% in 2022, then crashed by -1126bps to 794900.0% in 2023, then surged by 98bps to 18875.0% in 2024, then crashed by -189bps to 54600.0% in 2025.
  • Business Quant data shows EBIT Margin for TCRT at 54600.0% in Q1 2025, 18875.0% in Q4 2024, and 29150.0% in Q2 2024.